Official websites use .gov

A .gov website belongs to an official government organization in the United States.

Secure .gov websites use HTTPS

A lock ( 🔒 ) or https:// means you've safely connected to the .gov website. Share sensitive information only on official, secure websites.

Need Help

EBV-positive diffuse large B-cell lymphoma: defining biologic determinants of disease pathogenesis in immunodeficiency

Award Number: K08CA300927
ORGANIZATION: NATIONAL CANCER INSTITUTE
OPDIV: NIH
AWARD CLASS: DISCRETIONARY
AWARD ACTIVITY TYPE: TRAINING/TRAINEESHIP
PERIOD OF PERFORMANCE START DATE: 08/01/2026
PERIOD OF PERFORMANCE END DATE: 07/31/2031

Group Awards By:

View Award Description

EBV-positive diffuse large B-cell lymphoma: defining biologic determinants of disease pathogenesis in immunodeficiency - PROJECT SUMMARY Epstein-Barr virus (EBV)-associated diffuse large B-cell lymphoma (DLBCL) represents a clinically significant subtype often arising in immunodeficiency and defined viral latency states. Although proven in Western populations to confer worse outcomes and greater biologic aggression, the clinical impact and burden of disease for EBV(+) DLBCL is unknown, particularly in disparate immunodeficiency settings of endemic HIV arising in Southern Africa (SA) versus iatrogenic immunodeficiency in the United States (U.S.). Crucially, there is no diagnostic standard in defining EBV positivity in DLBCL, which is essential for pathologic diagnosis and disease categorization. The lack of diagnostic and prognostic biomarkers of disease limits our understanding of EBV- mediated pathogenesis and the development of much-needed targeted therapies. The overall goal of this project will be to correlate the genomic biology of EBV(+) DLBCL to clinical variables of immunodeficiency and outcome to improve diagnostics, uncover pathogenic mechanisms, and identify potential therapeutic targets in global patient cohorts. The study will pursue two specific aims: 1) Define the EBV latency status of DLBCL across distinct immunodeficiency settings using an established global cohort from SA and the U.S., 2) Define the epigenetic and transcriptional mechanisms by which EBV latency promotes immune evasion in EBV(+) DLBCL, using the established cohort. Outcomes from this study will advance our knowledge in EBV pathogenesis of DLBCL across immunodeficiencies, potentially identifying both diagnostic and prognostic biomarkers of disease and unveil therapeutic targets. Through this K08 Mentored Clinical Scientist Research Career Development Award, Dr. Volaric will develop the necessary skills in bioinformatics data analysis and processing as well as global health project management and leadership that will position her optimally to establish an independent research program. Dr. Volaric has assembled strong mentorship and scientific advisory teams, led by her primary mentor Dr. Seth Frietze, with expertise in EBV-mediated lymphomagenesis, multi-omics analysis, multiplex imaging, bioinformatics, biostatistics, biorepository management, and development of global research partnerships. With the team’s guidance and mentorship, Dr. Volaric will develop and strengthen her scientific skillsets to emerge as a leader in global lymphoma research and collaborative partnerships.


Issue Date FY	Funding FY	Legal Entity Name	Legal Entity Address	Legal Entity City	Legal Entity State	Legal Entity Zip Code	Legal Entity COUNTY	Legal Entity COUNTRY	Assistance Listing	Award Code	Budget Year	Action Date	Action Type	Action Amount

Issue Date FY: 2026 ( Subtotal = $276,862 )
2026	2026	UNIVERSITY OF VERMONT & STATE AGRICULTURAL COLLEGE	85 S PROSPECT STREET	BURLINGTON	VT	05405	CHITTENDEN	USA	Cancer Research Manpower	000	1	7/15/2026	NEW	$276,862
														Subtotal = $276,862

Grand Total All Awards = $276,862

Top

All Categories

About

Search

Reports

Data Submission

Award Information

EBV-positive diffuse large B-cell lymphoma: defining biologic determinants of disease pathogenesis in immunodeficiency

Award Number: K08CA300927

ORGANIZATION: NATIONAL CANCER INSTITUTE

OPDIV: NIH

AWARD CLASS: DISCRETIONARY

AWARD ACTIVITY TYPE: TRAINING/TRAINEESHIP

PERIOD OF PERFORMANCE START DATE: 08/01/2026

PERIOD OF PERFORMANCE END DATE: 07/31/2031

Federal Websites

Department of Health & Human Services

HHS Operating Divisions

HHS Staff Divisions

Download A Document Viewer